Sign inJoin waitlistJoin the waitlist

Gerburg Wulf

Physician · Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center

Credentials: · · · ·

History

Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center
Present

Beth Israel Deaconess Medical Center
1990–1992
Ruprecht-Karls University
1987–1990
Medizinische Fakultät, Westfälische Wilhelms-Universität Münster
1983–1987

Research

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Cancer Discovery · 2019 · 623 citations
The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
Nature · 1999 · 619 citations
Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA
Molecular Cell · 2003 · 574 citations

Eric Winer
12 papers
Adam Tobias
7 papers
Felipe Batalini
7 papers · 6 as a fellow
GB
Gabrielle Baker
7 papers
Geoffrey Shapiro
7 papers
IK
Ian Krop
7 papers
Nadine Tung
7 papers
Ursula Matulonis
7 papers
Panagiotis Konstantinopoulos
6 papers
Richard Bartlett
6 papers
VF
Valerie Fein-Zachary
6 papers
Alan D’Andrea
5 papers

Grants

Determinants of PARP-Inhibitor Response in Breast Cancer Patients Without Germline Mutations in BRCA1/2
National Cancer Institute · R21
Contact PI · $470.6K · Beth Israel Deaconess Medical Center
2025–2027
Gender-Affirming Testosterone Therapy on Breast Cancer Risk and Treatment Outcomes
National Cancer Institute · R56
PI · $299.9K · Beth Israel Deaconess Medical Center
2023–2025
Admin Suppl Gender-Affirming Estrogen Therapy and Breast Cancer Treatment Outcome
National Cancer Institute · R21
PI · $535.8K · Beth Israel Deaconess Medical Center
2021–2024
Novel Uses of PI3K-Inhibitors for the Treatment of Advanced PIK3CA-Mutant Breast Cancer
National Cancer Institute · R01
Contact PI · $2.1M · Beth Israel Deaconess Medical Center
2018–2023

Clinical trials

Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Principal investigator · Completed · Phase 1, Phase 2
Beth Israel Deaconess Medical Center
2007–2010
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Ensem Therapeutics
2025–2027
Study of ACR-2316 in Specific Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Acrivon Therapeutics
2024–2027
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2023–2028